Stifel Sees Apellis Pharmaceuticals (APLS) Up $7 on Bullish Empaveli Label
Tweet Send to a Friend
Stifel analyst Derek Archila reiterated a Buy rating and $67.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
